Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

224,881-224,910 of 319,975

filter-aware
20
The slide uses a before-and-after medical imaging comparison to demonstrate drug efficacy.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The table tracks 3 patients across different cancer types, detailing their age, prior treatments, adverse events, dose-limiting toxicities (DLT), cycles completed, response, and current disposition.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
22
The slide uses a process flow diagram to map patient segments to specific dosing regimens and clinical goals.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
23
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
24
The slide uses a 2x2 grid of metrics to frame the problem/opportunity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
25
Includes comparative context to historical studies (pazopanib, pembrolizumab).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
26
Includes decision criteria for 'Go'/'No Go' based on clinical response and PFS rates.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
27
Includes specific adverse event data and clinical observations.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
28
Details specific patient enrollment numbers (~80 total, ~60 for primary analysis) and dosing randomization criteria.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
29
The slide uses a grid of metrics to define the addressable market and the clinical problem (progression after 1L).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · Market Sizing1 hit
30
The slide presents clinical evidence linking AXL expression to poor patient outcomes in two different cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
31
The slide outlines a clinical trial protocol including patient disposition criteria and study endpoints.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
32
The table highlights the heavy pretreatment status of the patient population, specifically noting that a significant portion received 3 or more prior systemic therapies.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
33
Includes specific response rates, disease control rates, and confidence intervals for two patient cohorts.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
34
Waterfall plot shows best percentage change from baseline; spider plot shows change over time in weeks.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
35
This is a classic swimmer plot used in oncology clinical trials to visualize time-on-treatment and response status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
36
Includes PET scan imagery comparing baseline to post-treatment status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
37
Data presented at IASLC 2023 North America Conference on Lung Cancer.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
38
Data cut date: 30Jun23. Includes events occurring in >=15% of patients or grade >=3 in >=3% of patients.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
39
Mentions FDA Project Optimus, which is a regulatory initiative for dose optimization in oncology trials.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
40
The dashed box highlights the 'AXL low' expression group, showing significant anti-tumor activity.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
41
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
42
BioAtla | Investor Presentation Deck | 55 slidesBioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
43
Includes footnotes for data sources and a glossary of terms.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
44
The chart is a waterfall plot showing percentage change in tumor size. Red bars indicate partial response (PR).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
45
Uses a 2x2 grid layout to present key market metrics alongside current treatment efficacy benchmarks.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
46
Includes specific patient counts and clinical outcomes (responses, stable disease, progressive disease).BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
47
The slide uses a funnel-like logic to narrow down the addressable market from total prevalence to the 2L+ refractory segment.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
48
The slide uses a table to present clinical outcomes for specific cancer types, followed by a summary statement on the first-in-class status.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit
49
The table displays specific drug administration schedules for clinical evaluation.BioAtla | Investor Presentation Deck | 55 slides · BioAtla
Pitch deck Investor relations 1 hit